Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2018

01-12-2018 | ASO Author Reflections

ASO Author Reflections: Surgery and Bevacizumab in Ovarian Cancer

Authors: Marco Petrillo, MD, PhD, Giovanni Scambia, MD, PhD, Anna Fagotti, MD, PhD

Published in: Annals of Surgical Oncology | Special Issue 3/2018

Login to get access

Excerpt

In the past decade, several efforts have been made to improve medical and surgical management of advanced ovarian cancer (OC) patients, and even if this neoplasia remains a highly lethal malignancy, a trend toward a slow but continuous improvement in prognosis has been observed. In this context, the successful incorporation of bevacizumab into first-line chemotherapy certainly represents one of the most relevant advancements achieved.1,2 …
Literature
1.
Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.CrossRefPubMed
2.
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.CrossRefPubMed
3.
Eveno C, Passot G, Goére´ D, et al. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2014;21:1792–800.CrossRefPubMed
4.
Petrillo M, Nero C, Carbone V, Bruno M, Scambia G, Fagotti F. Systematic review of cytoreductive surgery and bevacizumab-containing chemotherapy in advanced ovarian cancer: focus on safety. Ann Surg Oncol. 2018;25:247–54.CrossRefPubMed
5.
Duska LR, Java JJ, Cohn DE, Burger RA. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). Gynecol Oncol. 2015;139:221–7.CrossRefPubMedPubMedCentral
Metadata
Title
ASO Author Reflections: Surgery and Bevacizumab in Ovarian Cancer
Authors
Marco Petrillo, MD, PhD
Giovanni Scambia, MD, PhD
Anna Fagotti, MD, PhD
Publication date
01-12-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-7024-2

Other articles of this Special Issue 3/2018

Annals of Surgical Oncology 3/2018 Go to the issue

ASO Author Reflections

ASO Author Reflections: To Med or Not to Med? That is the Question

ASO Author Reflections

ASO Author Reflections: Abandoning the Drains by Eliminating the Radical Procedures Necessitating the Drains

ASO Author Reflections

ASO Author Reflections: Treatment Approaches to Sinonasal Mucosal Melanoma

ASO Author Reflections

ASO Author Reflections: Central Lymph Node Status in the cN0 Tall-Cell Variant of Papillary Thyroid Cancer Deserves Further Attention in Clinical Practice

ASO Author Reflections

ASO Author Reflections: Tumor Markers in Gastric Cancer

ASO Author Reflections

ASO Author Reflections: Survival Impacts of Therapy and Complications in Gastric Adenocarcinoma